<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04339192</url>
  </required_header>
  <id_info>
    <org_study_id>B2020-036R</org_study_id>
    <nct_id>NCT04339192</nct_id>
  </id_info>
  <brief_title>Minimally Invasive Tricuspid Surgery vs Medical Treatment for Severe TR</brief_title>
  <official_title>Minimally Invasive Tricuspid Surgery Versus Medical Treatment for Severe Tricuspid Regurgitation After Left-sided Valve Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Zhongshan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Zhongshan Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Late tricuspid regurgitation (TR) is a common complication after left-sided valve surgery
      (LSVS), which usually progresses slowly and results in right heart failure at terminal stage.
      Over the past 3 decades, with the advances in minimally invasive surgical techniques,
      operative mortality after reoperation for severe TR has significantly decreased from 30% to
      3-8%, leading to a gradual shift from medical therapy alone to surgery in those patients.
      However, there has been no consensus on the clinical benefit of minimally invasive tricuspid
      surgery over medical therapy for severe TR after LSVS.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this multi-center randomized controlled trial, patients with severe TR after LSVS will be
      recruited. The patients will be randomly assigned to surgery plus medical therapy (surgery
      group) or medical therapy alone (control group). The primary outcome will be a composite of
      all-cause mortality, re-admission for right heart failure or the composite. Furthermore,
      echocardiography-based measurement of right heart function, New York Heart Association
      functional class, liver and kidney function, and quality of life will be compared between the
      2 groups. All outcomes will be assessed at baseline and 6, 12 and 24 months after
      randomization.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">May 1, 2020</start_date>
  <completion_date type="Anticipated">June 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the rate of all-cause death, re-hospitalization due to right heart failure or both of them</measure>
    <time_frame>2 years</time_frame>
    <description>the rate of all-cause death, re-hospitalization due to right heart failure or both of them</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>right heart function</measure>
    <time_frame>2 years</time_frame>
    <description>echocardiography-based measurement of right heart function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New York Heart Association functional class</measure>
    <time_frame>2 years</time_frame>
    <description>New York Heart Association functional class including I, II, III, IV class</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>liver function</measure>
    <time_frame>2 years</time_frame>
    <description>total bilirubin, conjugated bilirubin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>liver function</measure>
    <time_frame>2 years</time_frame>
    <description>prealbumin.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>kidney function</measure>
    <time_frame>2 years</time_frame>
    <description>blood urea nitrogen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>kidney function</measure>
    <time_frame>2 years</time_frame>
    <description>creatinine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>kidney function</measure>
    <time_frame>2 years</time_frame>
    <description>uric acid.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>life quality scores</measure>
    <time_frame>2 years</time_frame>
    <description>quality of life using the SF-12 form</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">330</enrollment>
  <condition>Tricuspid Regurgitation</condition>
  <arm_group>
    <arm_group_label>Surgery group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>receiving minimally invasive tricuspid surgery including tricuspid valve replacement or repair plus medical treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Medical group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>receiving medical treatment only</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Minimally Invasive Tricuspid Surgery</intervention_name>
    <description>minimally invasive tricuspid surgery including endoscopy-assist right minithoracotomy, vacuum-assist single femoral venous drainage without dissecting or snaring vena cava, direct right atriotomy through pericardium and the beating-heart technique.</description>
    <arm_group_label>Surgery group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Severe tricuspid regurgitation, as assessed by the clinical site echocardiographer
             using the transthoracic echocardiography.

          2. A history of LSVS, including one or multiple procedures of aortic and/or mitral valve
             repair and/or replacement.

          3. Left ventricular ejection fraction (LVEF) &gt;45%, systolic pulmonary artery pressure &lt;60
             mmHg with pulmonary vascular resistance &lt;6 woods unit.

          4. Age â‰¥ 18 years.

          5. Able to sign Informed Consent forms.

        Exclusion Criteria:

          1. TR due to: infective endocarditis, congenital tricuspid valve malformation, secondary
             to correction of congenital heart disease.

          2. Left-sided valve dysfunction or coronary artery disease requiring concomitant
             procedures.

          3. Prior surgical or percutaneous tricuspid valve intervention.

          4. Evidence of an acute myocardial infarction in the prior 90 days

          5. Contraindications to cardiopulmonary bypass or the expected operative mortality &gt;30%
             (calculated by the Society of Thoracic Surgeons score or the EuroSCORE II).

          6. Any comorbidity with life expectancy &lt;2 years

          7. Recent history of psychiatric disease (including drug or alcohol abuse) that is likely
             to impair compliance with the study protocol.

          8. Pregnancy at the time of randomization.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chunsheng Wang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Zhongshan Hospital, Fudan Univerisity</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jinmiao Chen, MD, PhD</last_name>
    <phone>+86 15121036927</phone>
    <email>chen.jinmiao@zs-hospital.sh.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Zhongshan Hospital, Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jinmiao Chen, MD, PhD</last_name>
      <phone>+86 15121036927</phone>
      <email>chen.jinmiao@zs-hospital.sh.cn</email>
    </contact>
    <investigator>
      <last_name>Chunsheng Wang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Chen J, Hu K, Ma W, Lv M, Shi Y, Liu J, Wei L, Lin Y, Hong T, Wang C. Isolated reoperation for tricuspid regurgitation after left-sided valve surgery: technique evolution. Eur J Cardiothorac Surg. 2020 Jan 1;57(1):142-150. doi: 10.1093/ejcts/ezz160.</citation>
    <PMID>31157373</PMID>
  </reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 5, 2020</study_first_submitted>
  <study_first_submitted_qc>April 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 9, 2020</study_first_posted>
  <last_update_submitted>April 8, 2020</last_update_submitted>
  <last_update_submitted_qc>April 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tricuspid Valve Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Now we have decided not to make IPD available to other researchers.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

